Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2007 8
2008 3
2009 2
2010 2
2012 1
2013 3
2014 3
2015 1
2016 3
2017 7
2018 8
2019 4
2020 8
2021 8
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S, Kawaoka T, Yamasaki S, Johira Y, Kosaka M, Shirane Y, Miura R, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Miki D, Tsuge M, Teraoka Y, Kouno H, Takaki S, Mori N, Tsuji K, Oka S. Yano S, et al. Among authors: mori n. Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406. Cancers (Basel). 2023. PMID: 38001666 Free PMC article.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Takaki S, Kurosaki M, Mori N, Tsuji K, Ochi H, Marusawa H, Nakamura S, Tada T, Narita R, Uchida Y, Akahane T, Kondo M, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Ogawa C, Sato T, Tamaki N, Yasui Y, Tsuchiya K, Izumi N. Takaki S, et al. Among authors: mori n. Invest New Drugs. 2023 Apr;41(2):340-349. doi: 10.1007/s10637-023-01349-4. Epub 2023 Mar 30. Invest New Drugs. 2023. PMID: 36995548
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kinami T, Yamasaki S, Kosaka M, Johira Y, Yano S, Naruto K, Ando Y, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Morio K, Moriya T, Naeshiro N, Nonaka M, Aisaka Y, Azakami T, Hiramatsu A, Aikata H, Oka S. Amioka K, et al. Among authors: mori n. Cancers (Basel). 2022 Oct 16;14(20):5066. doi: 10.3390/cancers14205066. Cancers (Basel). 2022. PMID: 36291850 Free PMC article.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C, Uchikawa S, Kawaoka T, Kinami T, Yano S, Amioka K, Naruto K, Ando Y, Yamaoka K, Tsuge M, Kosaka Y, Ohya K, Mori N, Takaki S, Tsuji K, Kouno H, Kohno H, Morio K, Moriya T, Nonaka M, Aisaka Y, Masaki K, Honda Y, Naeshiro N, Hiramatsu A, Aikata H, Oka S. Kikugawa C, et al. Among authors: mori n. Oncology. 2024;102(3):239-251. doi: 10.1159/000533859. Epub 2023 Sep 20. Oncology. 2024. PMID: 37729889
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R, Murakami S, Yano S, Naruto K, Ando Y, Kosaka Y, Fujii Y, Kodama K, Uchikawa S, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Imamura M, Mori N, Takaki S, Tsuji K, Masaki K, Honda Y, Kouno H, Kohno H, Moriya T, Naeshiro N, Nonaka M, Hyogo H, Aisaka Y, Azakami T, Hiramatsu A, Aikata H. Amioka K, et al. Among authors: mori n. Cancers (Basel). 2022 Jan 10;14(2):320. doi: 10.3390/cancers14020320. Cancers (Basel). 2022. PMID: 35053484 Free PMC article.
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. Tamaki N, et al. Among authors: mori n. Hepatol Commun. 2022 Mar;6(3):461-472. doi: 10.1002/hep4.1833. Epub 2021 Oct 22. Hepatol Commun. 2022. PMID: 34676692 Free PMC article.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Tamaki N, et al. Among authors: mori n. Invest New Drugs. 2022 Dec;40(6):1290-1297. doi: 10.1007/s10637-022-01303-w. Epub 2022 Sep 24. Invest New Drugs. 2022. PMID: 36152108
Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.
Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ, Chen PJ, Gaggar A, Suri V, Mücke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K, Liang TJ. Cheng X, et al. Among authors: mori n. J Clin Invest. 2020 Jun 1;130(6):3205-3220. doi: 10.1172/JCI135616. J Clin Invest. 2020. PMID: 32163375 Free PMC article.
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Naruto K, Kawaoka T, Amioka K, Ogawa Y, Chihiro K, Yoshikawa Y, Ando Y, Suehiro Y, Kosaka Y, Uchikawa S, Kodama K, Morio K, Fujino H, Murakami E, Nakahara T, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Takaki S, Mori N, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Kohno H, Kohno H, Moriya T, Naeshiro N, Azakami T, Imamura M, Chayama K, Aikata H. Naruto K, et al. Among authors: mori n. Oncology. 2021;99(8):491-498. doi: 10.1159/000515280. Epub 2021 May 17. Oncology. 2021. PMID: 34000725
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Ochi H, Kurosaki M, Joko K, Mashiba T, Tamaki N, Tsuchiya K, Marusawa H, Tada T, Nakamura S, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Izumi N. Ochi H, et al. Among authors: mori n. Hepatol Res. 2023 Jan;53(1):61-71. doi: 10.1111/hepr.13836. Epub 2022 Oct 4. Hepatol Res. 2023. PMID: 36070216
65 results